September 8, 2005 An FDA panel recommended the inhaled form of insulin, Exubera, from Pfizer, Sanofi-Aventis and Nektar; Barr Labs will pay $142 million to acquire a contraceptive from Organon and Savient Pharma; Caliper Life Sciences will pay $22 million to buy NovaScreen Biosciences, which offers research services; Indevus began a Phase III trial of its overactive bladder drug; and animal rights activists prevented Life Sciences Research from listing on the NYSE. Biotech executed a small retreat on Thursday, with the Centient Biotech 200 losing almost 16 points to close at 3890.31, a drop of .41%. More details...
